Furthermore, sIL-2R can affect the response to infliximab in RA patients, and a low serum sIL-2R level predicts rapid response to infliximab [100], suggesting that IL-2-sIL-2R activation may affect the response to anti-TNF-α treatment in RA patients with CS. This evidence concerns the gene TNF and rheumatoid arthritis.